Voltammetric behavior of antileukemia drug glivec. Part II - Redox processes of glivec electrochemical metabolite

被引:16
作者
Diculescu, Victor Constantin
Vivan, Marilene
Brett, Ana Maria Oliveira [1 ]
机构
[1] Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal
[2] Hosp Univ Coimbra, P-3000 Coimbra, Portugal
关键词
glivec metabolite; electrochemistry; voltammetry; standard potential; rate constant; adsorption;
D O I
10.1002/elan.200603592
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Glivec is a newly developed drug that belongs to the class of 2-phenylaminopyrimidine. It is a potent inhibitor of ABL-kinase, the main clinical manifestation of chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation for its activity against other tumor types. Detection and quantitation of glivec in biological fluids or cells is thus very important. The antileukemia drug glivec undergoes oxidation at glassy carbon electrodes and involves the formation of an oxidation product, P-glivec. The adsorption of P-glivec at the GCE surface yields a compact monolayer allowing an electrochemical study of this compound adsorbed at the GCE surface. The reversible redox reaction of the adsorbed P-glivec is pH dependent and occurs with the transfer of 2 electrons and 2 protons. The surface standard potential and the rate constant of the heterogeneous electrochemical reaction were calculated using cyclic voltammetry to be E-theta'= + 180 mV and k = 15.5 s(-1), respectively. The total surface concentration of adsorbed P-glivec is 2.5 x 10(-12) Mol cm(-2). The analytical determination of glivec was carried out by differential pulse voltammetric measurement of the anodic peak current corresponding to either the oxidation peak of glivec or the oxidation peak of P-glivec adsorbed on the GCE surface. The limits of detection of glivec and adsorbed P-glivec based on three times the noise level are 3.3 x 10(-8) M and 2.9 x 10(-10) M, respectively.
引用
收藏
页码:1808 / 1814
页数:7
相关论文
共 23 条
  • [1] High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry
    Bakhtiar, R
    Lohne, J
    Ramos, L
    Khemani, L
    Hayes, M
    Tse, F
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02): : 325 - 340
  • [2] Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry
    Bakhtiar, R
    Khemani, L
    Hayes, M
    Bedman, T
    Tse, F
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) : 1183 - 1194
  • [3] Brett CMA, 1993, Electrochemistry: Principles, Methods, and Applications
  • [4] CYCLIC AND DIFFERENTIAL PULSE VOLTAMMETRIC BEHAVIOR OF REACTANTS CONFINED TO ELECTRODE SURFACE
    BROWN, AP
    ANSON, FC
    [J]. ANALYTICAL CHEMISTRY, 1977, 49 (11) : 1589 - 1595
  • [5] BUCHDUNGER E, 2001, BIOCHIM BIOPHYS ACTA, V151, pM11
  • [6] Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine
    Flores, JR
    Berzas, J
    Castañeda, G
    Rodríguez, N
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 794 (02): : 381 - 388
  • [7] Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry
    Guetens, G
    De Boeck, G
    Highley, M
    Dumez, H
    Van Oosterom, AT
    de Bruijn, EA
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2003, 1020 (01) : 27 - 34
  • [8] Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
    Hoser, G
    Majsterek, I
    Romana, DL
    Slupianek, A
    Blasiak, J
    Skorski, T
    [J]. LEUKEMIA RESEARCH, 2003, 27 (03) : 267 - 273
  • [9] Hubbard A. T., 1970, ELECTROANALYTICAL CH, V4, P129
  • [10] Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec® capsules
    Ivanovic, D
    Medenica, M
    Jancic, B
    Malenovic, A
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 800 (1-2): : 253 - 258